PURPOSE:To characterize cerebral glucose metabolism associated with different cognitive states in Parkinson's disease (PD) using 18F-fluorodeoxyglucose (FDG) and Positron Emission Tomography (PET). METHODS:Three groups of patients were recruited in this study including PD patients with dementia (PDD; n = 10), with mild cognitive impairment (PD-MCI; n = 20), and with no cognitive impairment (PD-NC; n = 30). The groups were matched for age, sex, education, disease duration, motor disability, levodopa equivalent dose and Geriatric Depression Rating Scale (GDS) score. All subjects underwent a FDG-PET study. Maps of regional metabolism in the three groups were compared using statistical parametric mapping (SPM5). RESULTS:PD-MCI patients exhibite...
Purpose The purpose of the study was the identification of group and individual subject patterns ...
Background: Visual hallucination (VH) is a common psychotic symptom in patients with Parkinson&rsquo...
Objective: Using 6-[18F]fluoro-l-dopa (FDOPA) and [18F]fluorodeoxyglucoce (FDG) positron emission to...
$\textbf{Objective}$ To assess reductions of cerebral glucose metabolism in Parkinson’s disease (PD)...
PURPOSE: Cognitive impairment (CI) in Parkinson's disease (PD) is associated with a widespread reduc...
OBJECTIVE: To characterize brain metabolic changes associated with mild cognitive impairment (MCI) ...
BACKGROUND: Half of Parkinson's disease (PD) patients with mild cognitive impairment (MCI) develop d...
Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) share many similar aspects, a...
Despite controversial clinicopathological distinctions between Parkinson's disease with dementia (PD...
The differentiation between progressive supranuclear palsy (PSP) and Parkinson's disease (PD) may be...
The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, esp...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
Parkinson's disease is a neurodegenerative movement disorder with cognitive symptoms with similariti...
Background: Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with faster cogn...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
Purpose The purpose of the study was the identification of group and individual subject patterns ...
Background: Visual hallucination (VH) is a common psychotic symptom in patients with Parkinson&rsquo...
Objective: Using 6-[18F]fluoro-l-dopa (FDOPA) and [18F]fluorodeoxyglucoce (FDG) positron emission to...
$\textbf{Objective}$ To assess reductions of cerebral glucose metabolism in Parkinson’s disease (PD)...
PURPOSE: Cognitive impairment (CI) in Parkinson's disease (PD) is associated with a widespread reduc...
OBJECTIVE: To characterize brain metabolic changes associated with mild cognitive impairment (MCI) ...
BACKGROUND: Half of Parkinson's disease (PD) patients with mild cognitive impairment (MCI) develop d...
Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB) share many similar aspects, a...
Despite controversial clinicopathological distinctions between Parkinson's disease with dementia (PD...
The differentiation between progressive supranuclear palsy (PSP) and Parkinson's disease (PD) may be...
The differential diagnosis of neurodegenerative brain diseases on clinical grounds is difficult, esp...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
Parkinson's disease is a neurodegenerative movement disorder with cognitive symptoms with similariti...
Background: Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with faster cogn...
We investigated changes in cerebral glucose metabolism after cholinesterase inhibitor (ChEI) therapy...
Purpose The purpose of the study was the identification of group and individual subject patterns ...
Background: Visual hallucination (VH) is a common psychotic symptom in patients with Parkinson&rsquo...
Objective: Using 6-[18F]fluoro-l-dopa (FDOPA) and [18F]fluorodeoxyglucoce (FDG) positron emission to...